Gullestad, L., Ueland, T., Kjekshus, J., Nymo, S. H, Hulthe, J., Muntendam, P., McMurray, J. J, Wikstrand, J. & Aukrust, P. (2012). The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). American Heart Journal,164(6), 878-883. United States: Mosby Inc.. Retrieved from https://doi.org/10.1016/j.ahj.2012.08.021
Galectin-3 is a new biomarker involved in inflammation and fibrogenesis and could therefore contribute to myocardial remodeling. We examined the prognostic value of baseline galectin-3 in a substudy involving approximately 30% of participants in the CORONA study.
Mary MacKillop Institute for Health Research
Access may be restricted.